Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from ...

The Brief A pilot program by the Centers for Medicare and Medicaid could increase coverage for weight-loss drugs like Ozempic and Zepbound. The pilot program would allow state Medicaid programs ...

The pilot program would allow state Medicaid programs and Medicare Part D insurance plans to choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for weight loss.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Brief A pilot program by the Centers for Medicare and Medicaid could increase coverage for weight-loss drugs like Ozempic and Zepbound. The pilot program would allow state Medicaid programs and ...

By Patrick Wingrove (Reuters) -Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of ...

Any approvals would not apply to Eli Lilly's weight loss drug Zepbound, which shares the same active ingredient as Mounjaro but is specifically cleared for patients with obesity and not diabetes.

The strategy is playing out globally, with Novo Nordisk and Eli Lilly providing high-profile examples of repurposing GLP-1 drugs – originally developed for type 2 diabetes – for weight loss.